IT'S TIME TO TREAT PMDD
SEPRANOLONE: Remain in control of your life
Asarina Pharma AB (publ) Interim Report, Q1 2019 released
Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019
REMAIN IN CONTROL OF YOUR LIFE
“When I first saw PMDD symptoms described it was like a lightbulb switching on… Finally, I thought, I’m not alone. I can begin to take back control!” ‘Lisa’, 37, UK.
The more we know about PMDD, the more power we have over it. PMDD disrupts women’s work and family lives. Yet it’s still widely undiagnosed. With over 40 years of research we’re helping build support and raise awareness of what really causes PMDD, and the reality behind the myths.
Sepranolone has been built on over 40 years’ research. It all started in 1972, before “PMDD” even existed…
Sepranolone is the world’s first therapy specifically developed to treat PMDD. Neither a hormone nor an anti-depressant, in Phase IIA clinical trials it achieved over 80% reduction of key PMDD symptoms among 120 patients. And proved highly safe and tolerable.
We’re now running Phase IIB trials of Sepranolone in Germany, Poland, Sweden and the UK.
‘Therese’, 38, Germany
Menstrual Migraine is a disabling form of migraine with severe, prolonged attacks. It impacts approx. 50 million women worldwide. MM is often resistant to current standard treatments.
Yet there has never been a specific therapy to treat it. Until now. Our Phase IIA trial for Sepranolone—a prophylactic treatment designed to prevent Menstrual Migraine symptoms from even occurring—is now underway.
INVEST IN WOMEN'S HEALTH
THE PASSION OF PATIENTS
“The patients we’re recruiting are highly motivated. I think they’re proud to be involved, they know this drug won’t be available instantly after the trial, but they’re committed to volunteering so other women won’t have to suffer like they have…”
DR PAULA BRIGGS, LEAD STUDY INVESTIGATOR, LIVERPOOL WOMAN’S HOSPITAL, CONSULTANT IN SEXUAL AND REPRODUCTIVE HEALTH
Our Phase IIB clinical study into PMDD is taking place in 12 study centers in 4 countries and will run with over 200 patients.